ID
13423
Beschrijving
Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.
Trefwoorden
Versies (3)
- 04-02-16 04-02-16 -
- 11-02-16 11-02-16 -
- 11-02-16 11-02-16 -
Geüploaded op
11 februari 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation DRKS00000084 NCT01143272
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation NCT01143272
Beschrijving
Treatment with drugs/opiates causing constipation
Beschrijving
line
Datatype
integer
Beschrijving
medication name
Datatype
text
Alias
- UMLS CUI [1]
- C2360065
Beschrijving
first dose
Datatype
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Beschrijving
Date of first dose unknown
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0011008
Beschrijving
Date of last dose
Datatype
date
Alias
- UMLS CUI [1]
- C1762893
Beschrijving
Date of last dose unknown
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1762893
- UMLS CUI [1,2]
- C0439673
Beschrijving
Treatment with systemic antifungal agents; note that the use of systemic antifungal agents makes the patient retrospectively ineligible for this study as of exclusion criterion 06; please record early study termination if this is the case
Beschrijving
Line
Datatype
integer
Beschrijving
medication name
Datatype
text
Alias
- UMLS CUI [1]
- C2360065
Beschrijving
first dose
Datatype
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Beschrijving
Date of first dose unknown
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0011008
Beschrijving
Date of last dose
Datatype
date
Alias
- UMLS CUI [1]
- C1762893
Beschrijving
Date of last dose unknown
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1762893
- UMLS CUI [1,2]
- C0439673
Similar models
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation NCT01143272
C1515021 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0003232 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0439673 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0439673 (UMLS CUI [1,2])
Geen commentaren